Trial Profile

Oral anticoagulant agent-associated bleeding events reporting system (ORANGE study)

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 23 May 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Warfarin (Primary) ; Prothrombin complex concentrate
Indications Thrombosis
Focus Adverse reactions
Acronyms ORANGE

Most Recent Events

23 May 2020 New trial record
30 Mar 2020 Results (n=410) assessing NOAC related major bleeding by conducting indirect comparison using data ANNEXA-4 and ORANGE studies, presented at the 2020 Annual Scientific Session of the American College of Cardiology and World Congress of Cardiology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com